Side-by-side comparison of AI visibility scores, market position, and capabilities
New York multi-studio fitness membership for yoga, cycling, and spa across 30+ countries; Mindbody-acquired competing with Gympass/Wellhub for multi-venue fitness subscription and corporate wellness benefits.
ClassPass is a New York-based fitness and wellness membership platform providing access to thousands of gyms, yoga studios, pilates, cycling, strength training, spa, and beauty services through a single subscription — enabling members to sample multiple fitness and wellness experiences rather than committing to a single-location gym membership. Acquired by Mindbody (in turn backed by Vista Equity Partners) in 2021 for approximately $500-700 million, ClassPass serves millions of members across 30+ countries, generating estimated $400+ million in annual revenue and becoming the largest multi-venue fitness subscription platform globally.
Rare disease biotech developing polytherapy approach for Rett Syndrome (1 in 10,000 girls); founder-developed protocol validated through personal patient experience competing with Acadia Pharmaceuticals Daybue in Rett market.
Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1 in 10,000 girls — applying a polytherapy approach (combining multiple therapeutic agents targeting different disease mechanisms simultaneously) to develop treatments for serious neurological and rare diseases. After improving his daughter's quality of life through a personally developed polytherapy protocol, Auerhahn founded Uncommon Therapeutics to translate these insights into pharmaceutical products for the broader Rett Syndrome patient community.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.